Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

64.56B

Market cap64.56B

Price-Earnings ratio

14.90

Price-Earnings ratio14.90

Dividend yield

0.60%

Dividend yield0.60%

Average volume

1.26M

Average volume1.26M

High today

$628.90

High today$628.90

Low today

$610.95

Low today$610.95

Open price

$623.89

Open price$623.89

Volume

1.02M

Volume1.02M

52 Week high

$821.11

52 Week high$821.11

52 Week low

$494.42

52 Week low$494.42

Stock Snapshot

Regeneron(REGN) stock is priced at $616.18, giving the company a market capitalization of 64.56B. It carries a P/E multiple of 14.90 and pays a dividend yield of 59.5%.

During the trading session on 2026-06-09, Regeneron(REGN) shares reached a daily high of $628.90 and a low of $610.95. At a current price of $616.18, the stock is +0.9% higher than the low and still -2.0% under the high.

Trading volume for Regeneron(REGN) stock has reached 1.02M, versus its average volume of 1.26M.

The stock's 52-week range extends from a low of $494.42 to a high of $821.11.

REGN News

CNBC 1d

Regeneron CEO Leonard Schleifer on the power of the Constitution - CNBC

...

Simply Wall St 4d

Kodiak Sciences Zenkuda Trial Win Puts Cash Needs And Growth In Focus

Kodiak Sciences (NasdaqGM:KOD) reported positive phase III results for its drug candidate Zenkuda in diabetic retinopathy. The company is accelerating regulato...

TipRanks 5d

RAPID Real‑World Dupixent Data Could Extend Regeneron and Sanofi’s Asthma Edge

Regeneron Pharmaceuticals (REGN), Sanofi (SNYNF) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks...

Analyst ratings

74%

of 31 ratings

Buy

74.2%

Hold

25.8%

Sell

More REGN News

Seeking Alpha 5d

Regeneron backed Parabilis seeks up to $476M in U.S. IPO

Parabilis Medicines (PBLS), a cancer drug developer backed by a recent research collaboration with Regeneron (REGN), has announced plans to raise up to $476M fr...

TipRanks 6d

CytomX Expands High-Value Bispecific Cancer Partnership With Regeneron

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Seeking Alpha 6d

CytomX gains as licensing deal with Regeneron expands

CytomX Therapeutics (CTMX) traded higher in the morning hours on Wednesday after the cancer drug developer announced an expanded collaboration and licensing agr...

TipRanks 6d

CytomX Therapeutics expands licensing agreement with Regeneron

CytomX Therapeutics (CTMX) announced an expansion of its collaboration and licensing agreement with Regeneron Pharmaceuticals (REGN) to create conditionally-act...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.